HRP20151369T1 - Liksisenatid i metformin za lijeäśenje dijabetesa tipa 2 - Google Patents
Liksisenatid i metformin za lijeäśenje dijabetesa tipa 2 Download PDFInfo
- Publication number
- HRP20151369T1 HRP20151369T1 HRP20151369TT HRP20151369T HRP20151369T1 HR P20151369 T1 HRP20151369 T1 HR P20151369T1 HR P20151369T T HRP20151369T T HR P20151369TT HR P20151369 T HRP20151369 T HR P20151369T HR P20151369 T1 HRP20151369 T1 HR P20151369T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical combination
- use according
- subject
- treated
- mmol
- Prior art date
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims 3
- 229960003105 metformin Drugs 0.000 title claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims 3
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 title 1
- 229960001093 lixisenatide Drugs 0.000 title 1
- 108010004367 lixisenatide Proteins 0.000 title 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 claims 3
- 229940100389 Sulfonylurea Drugs 0.000 claims 2
- 235000012054 meals Nutrition 0.000 claims 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 2
- 102000051325 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000000291 postprandial effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (13)
1. Farmaceutska kombinacija za uporabu za smanjivanje razine glukagona u plazmi kod pacijenta s dijabetesom tipa 2, naznačena time da navedena kombinacija sadrži
(a) desPro36Exendin-4(1-39)-Lys6-NH2 ili/i njegovu farmaceutski prihvatljivu sol,
(b) metformin ili/i njegovu farmaceutski prihvatljivu sol, i
(c) sulfonil ureu,
pri čemu subjekt koji se liječi ima koncentraciju glukoze u plazmi 2 sata nakon obroka od barem 14 mmol/L.
2. Farmaceutska kombinacija za uporabu prema zahtjevu 1, naznačena time da je subjekt koji se liječi pretio.
3. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da subjekt koji se liječi ima indeks tjelesne mase od barem 30 kg/m2.
4. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da subjekt koji se liječi je odrasli subjekt.
5. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je kod subjekta koji se liječi, dijabetes melitus tipa 2 dijagnosticiran najmanje 1 godinu ili najmanje 2 godine prije početka terapije.
6. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da subjekt koji se liječi ima vrijednost HbA1C od oko 7 do oko 10%.
7. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da subjekt koji se liječi ima koncentraciju glukoze u plazmi natašte od barem 8 mmol/L.
8. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da subjekt koji se liječi ima promjenu razine glukoze od barem 2 mmol/L, najmanje 3 mmol/L, najmanje 4 mmol/L ili najmanje 5 mmol/L, pri čemu je promjena razine glukoze razlika između koncentracije glukoze u plazmi 2 sata nakon obroka i koncentracije glukoze u plazmi 30 minuta prije testa sa objedom.
9. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je subjekt koji se liječi orijentalne ili/i azijske rase.
10. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je desPro36Exendin-4(1-39)-Lys6-NH2 ili/i njegova farmaceutski prihvatljiva sol pripremljena za parenteralno davanje.
11. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je desPro36Exendin-4(1-39)-Lys6-NH2 ili/i njegova farmaceutski prihvatljiva sol pripremljena za davanje u dnevnoj dozi odabranoj u raspona od 10 µg do 20 µg.
12. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je metformin ili/i njegova farmaceutski prihvatljiva sol pripremljena za oralno davanje.
13. Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je sulfonil urea pripremljena za oralno davanje.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166120 | 2011-05-13 | ||
| EP12163637 | 2012-04-10 | ||
| PCT/EP2012/058747 WO2012156298A1 (en) | 2011-05-13 | 2012-05-11 | Lixisenatide and metformin for treatment of diabetes type 2 |
| EP12723132.2A EP2707017B1 (en) | 2011-05-13 | 2012-05-11 | Lixisenatide and metformin for treatment of diabetes type 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151369T1 true HRP20151369T1 (hr) | 2016-01-15 |
Family
ID=46148833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151369TT HRP20151369T1 (hr) | 2011-05-13 | 2015-12-11 | Liksisenatid i metformin za lijeäśenje dijabetesa tipa 2 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20130065828A1 (hr) |
| EP (1) | EP2707017B1 (hr) |
| JP (2) | JP6442284B2 (hr) |
| KR (1) | KR20140043755A (hr) |
| CN (2) | CN103841988A (hr) |
| AU (1) | AU2012257849B2 (hr) |
| BR (1) | BR112013029062A2 (hr) |
| CA (1) | CA2835259C (hr) |
| CY (1) | CY1117250T1 (hr) |
| DK (1) | DK2707017T3 (hr) |
| ES (1) | ES2556466T3 (hr) |
| HK (1) | HK1194307A1 (hr) |
| HR (1) | HRP20151369T1 (hr) |
| HU (1) | HUE028459T2 (hr) |
| MX (1) | MX362527B (hr) |
| PL (1) | PL2707017T3 (hr) |
| PT (1) | PT2707017E (hr) |
| RU (1) | RU2623023C2 (hr) |
| SI (1) | SI2707017T1 (hr) |
| WO (1) | WO2012156298A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3228320B1 (de) | 2008-10-17 | 2019-12-18 | Sanofi-Aventis Deutschland GmbH | Kombination von einem insulin und einem glp-1-agonisten |
| UY33025A (es) | 2009-11-13 | 2011-06-30 | Sanofi Aventis Deustschland Gmbh | Composicion farmaceutica que comprende un agonista de glp-1 metionina |
| AR080669A1 (es) | 2009-11-13 | 2012-05-02 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina |
| MX339614B (es) | 2010-08-30 | 2016-06-02 | Sanofi - Aventis Deutschland GmbH | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| RU2650616C2 (ru) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| CN114939156A (zh) | 2014-01-09 | 2022-08-26 | 赛诺菲 | 门冬胰岛素的稳定化药物制剂 |
| RU2016132386A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных |
| WO2015104314A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| US20160235818A1 (en) * | 2015-01-16 | 2016-08-18 | Sanofi-Aventis Deutschland Gmbh | Treatment of Pediatric Type 2 Diabetes Mellitus Patients |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| WO2020023388A1 (en) * | 2018-07-23 | 2020-01-30 | Eli Lilly And Company | Method of using a gip/glp1 co-agonist for diabetes |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| AU2005271526B2 (en) * | 2004-08-03 | 2011-12-08 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
| CN101291685A (zh) * | 2005-08-19 | 2008-10-22 | 安米林药品公司 | 治疗糖尿病和降低体重的毒蜥外泌肽 |
| JP5399244B2 (ja) * | 2006-08-17 | 2014-01-29 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド |
| CN106177958A (zh) * | 2009-02-13 | 2016-12-07 | 勃林格殷格翰国际有限公司 | 包含dpp‑4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物 |
| PT2324853E (pt) | 2009-11-13 | 2015-11-30 | Sanofi Aventis Deutschland | Lixisenatida como adjuvante da metformina no tratamento de diabetes do tipo 2 |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
-
2012
- 2012-05-11 PL PL12723132T patent/PL2707017T3/pl unknown
- 2012-05-11 EP EP12723132.2A patent/EP2707017B1/en not_active Revoked
- 2012-05-11 KR KR1020137033310A patent/KR20140043755A/ko active Search and Examination
- 2012-05-11 SI SI201230377T patent/SI2707017T1/sl unknown
- 2012-05-11 PT PT127231322T patent/PT2707017E/pt unknown
- 2012-05-11 CN CN201280034737.4A patent/CN103841988A/zh active Pending
- 2012-05-11 CN CN201711058028.0A patent/CN107693782A/zh active Pending
- 2012-05-11 US US13/469,633 patent/US20130065828A1/en not_active Abandoned
- 2012-05-11 JP JP2014509752A patent/JP6442284B2/ja active Active
- 2012-05-11 RU RU2013155474A patent/RU2623023C2/ru active
- 2012-05-11 MX MX2013013307A patent/MX362527B/es active IP Right Grant
- 2012-05-11 BR BR112013029062A patent/BR112013029062A2/pt not_active Application Discontinuation
- 2012-05-11 AU AU2012257849A patent/AU2012257849B2/en active Active
- 2012-05-11 DK DK12723132.2T patent/DK2707017T3/en active
- 2012-05-11 ES ES12723132.2T patent/ES2556466T3/es active Active
- 2012-05-11 WO PCT/EP2012/058747 patent/WO2012156298A1/en active Application Filing
- 2012-05-11 CA CA2835259A patent/CA2835259C/en active Active
- 2012-05-11 HU HUE12723132A patent/HUE028459T2/en unknown
-
2014
- 2014-08-04 HK HK14107943.7A patent/HK1194307A1/xx not_active IP Right Cessation
-
2015
- 2015-12-11 HR HRP20151369TT patent/HRP20151369T1/hr unknown
- 2015-12-15 CY CY20151101144T patent/CY1117250T1/el unknown
-
2018
- 2018-07-20 JP JP2018136356A patent/JP6676108B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6442284B2 (ja) | 2018-12-19 |
| BR112013029062A2 (pt) | 2016-11-29 |
| CN107693782A (zh) | 2018-02-16 |
| DK2707017T3 (en) | 2016-01-04 |
| HUE028459T2 (en) | 2016-12-28 |
| PT2707017E (pt) | 2016-01-12 |
| JP2018184441A (ja) | 2018-11-22 |
| KR20140043755A (ko) | 2014-04-10 |
| JP6676108B2 (ja) | 2020-04-08 |
| WO2012156298A1 (en) | 2012-11-22 |
| CY1117250T1 (el) | 2017-04-05 |
| JP2014514356A (ja) | 2014-06-19 |
| EP2707017A1 (en) | 2014-03-19 |
| AU2012257849B2 (en) | 2017-03-30 |
| CA2835259A1 (en) | 2012-11-22 |
| CA2835259C (en) | 2020-01-07 |
| RU2013155474A (ru) | 2015-06-20 |
| US20130065828A1 (en) | 2013-03-14 |
| PL2707017T3 (pl) | 2016-03-31 |
| EP2707017B1 (en) | 2015-09-16 |
| ES2556466T3 (es) | 2016-01-18 |
| MX362527B (es) | 2019-01-23 |
| MX2013013307A (es) | 2014-03-12 |
| CN103841988A (zh) | 2014-06-04 |
| RU2623023C2 (ru) | 2017-06-21 |
| SI2707017T1 (sl) | 2016-01-29 |
| HK1194307A1 (en) | 2014-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151369T1 (hr) | Liksisenatid i metformin za lijeäśenje dijabetesa tipa 2 | |
| HRP20151068T1 (hr) | Farmaceutska kombinacija za upotrebu za glikemijsku kontrolu kod pacijenata s dijabetesom tipa 2 | |
| HRP20161620T1 (hr) | Uporaba ave0010 za proizvodnju lijeka za liječenje dijabetes melitusa tip 2 | |
| HRP20121029T4 (hr) | Liksisenatid kao pomoćna terapija uz inzulin glargin i metformin kod liječenja dijabetesa tip 2 | |
| Sokar et al. | Combination of Sitagliptin and Silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats | |
| RU2013155473A (ru) | Фармацевтическая комбинация для применения для индуцирования потери массы тела у субъектов с диабетом 2 типа или/и для предотвращения набора массы тела у субъектов с диабетом 2 типа | |
| MX2014013105A (es) | Composiciones de activador de glucocinasa para el tratamiento de la diabetes. | |
| RU2017129878A (ru) | Фармацевтическая комбинация для применения в лечении пациентов с диабетом 2 типа | |
| Paolisso et al. | Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? | |
| AR078517A1 (es) | Composicion farmaceutica, forma de dosificacion farmaceutica, procedimiento para su preparacion, metodos para su tratamiento y sus usos | |
| HRP20151230T1 (hr) | Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2 | |
| HRP20151087T1 (hr) | Prevencija hipoglikemije kod pacijenata s dijabetesom tipa 2 | |
| BR112015007685A2 (pt) | derivados de exendina-4 como agonistas duplos de glp1/glucagon | |
| Ma et al. | heme oxygenase-1 agonist CoPP suppresses influenza virus replication through IRF3-mediated generation of IFN-α/β | |
| JP2011241213A5 (hr) | ||
| JP2018503644A5 (hr) | ||
| RU2013155481A (ru) | Ликсисенатид в качестве дополнительной терапии к базальному инсулину при диабете 2 типа | |
| AR078812A1 (es) | Preparacion que comprende aminoacidos y plantas y su actividad en la detoxificacion del alcohol | |
| HRP20230470T1 (hr) | Formulacija fiksnog omjera inzulin glargin/liksisenatid | |
| Wu et al. | Effects of metformin on endothelial function in type 2 diabetes | |
| EA201792030A1 (ru) | Лечение пациентов с сахарным диабетом 2 типа | |
| Mu et al. | Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naive Asian patients with type 2 diabetes | |
| BR112013030171A2 (pt) | composição comestível, método para reduzir a amplitude de pico de glicose pós-prandial no sangue ou resposta glicêmica em uma pessoa não diabética, método para tratar uma pessoa com necessidade de tratamento para diabetes do tipo 2 e uso da composição | |
| JP2011105610A5 (hr) | ||
| CL2013003556A1 (es) | Compuestos derivados de ftalazinona-pirrolo[3,2-d]pirimidin-carboxamida, inhibidoers de fosfodiesterasa tipo 4 y tipo 5; composcin farmaceutica que o comprende, combinacion fija, no fija y kit, uso del compuesto en la preparacion de un medicamento para trata enfermedaes de las vias respiratorias |